Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer

International Journal of Urology

Volumn 17, Issue 5, 2010, Pages 466-475

  Okegawa, Takatsugu ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Circulating tumor cells; Hormone refractory prostate cancer; Methylation; Prognosis

Indexed keywords

BICALUTAMIDE; EPITHELIAL CELL ADHESION MOLECULE; FLUTAMIDE; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 2; PROSTATE SPECIFIC ANTIGEN; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER SURVIVAL; CELL ISOLATION; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL; TUMOR EMBOLISM;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; CELL COUNT; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE S-TRANSFERASE PI; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; P-GLYCOPROTEIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77951274075     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02502.x     Document Type: Article

References (30)

1. Lembessis P, Msaouel P, Halapas A et al. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin. Chem. Lab. Med. 2007 45 : 1488 1494.
2. Joung JY, Yang SO, Jeong IG et al. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer. Int. J. Urol. 2007 14 : 635 643.
3. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin. Exp. Metastasis 2004 21 : 495 505.
4. Kurek R, Nunez G, Tselis N et al. Prognostic value of combined 'triple'-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin. Cancer Res. 2004 10 : 5808 5814.
5. Koutsilieris M, Lembessis P, Luu-The V, Sourla A. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin. Exp. Metastasis 1999 17 : 823 830.
6. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008 14 : 6302 6309.
7. Scher HI, Jia X, de Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009 10 : 233 239.
8. Bastian PJ, Ellinger J, Wellmann A et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res. 2005 11 : 4097 4106.
9. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev. 1998-1999 17 : 401 409.
10. Henderson CJ, McLaren AW, Moffat GJ, Bacon EJ, Wolf CR. Pi-class glutathione S-transferase: regulation and function. Chem. Biol. Interact. 1998 111-112 : 69 82.
11. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997 18 : 641 644.
12. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002 21 : 6835 6840.
13. Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J. Urol. 2008 180 : 1342 1347.
14. Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004 64 : 1975 1986.
15. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988 61 : 195 202.
16. Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J. Urol. 2004 172 : 141 145.
17. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005 65 : 713 718.
18. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 2007 13 : 7053 7058. (Pubitemid 350276887)
19. Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J. Urol. 2009 181 : 1091 1097.
20. Jerónimo C, Usadel H, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002 60 : 1131 1135.
21. Chu DC, Chuang CK, Fu JB, Huang HS, Tseng CP, Sun CF. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J. Urol. 2002 167 : 1854 1858.
22. Bastian PJ, Palapattu GS, Yegnasubramanian S et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J. Urol. 2008 179 : 529 534.
23. Ellinger J, Bastian PJ, Jurgan T et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008 71 : 161 167.
24. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 2004 202 : 233 240.
25. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 2002 8 : 514 519.
26. Brooks JD, Weinstein M, Lin X et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers. Prev. 1998 7 : 531 536.
27. Jerónimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. 2001 93 : 1747 1752.
28. Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev. 2007 31 : 59 63.
29. Stroun M, Maurice P, Vasioukhin V et al. The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 2000 906 : 161 168.
30. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001 61 : 1659 1665.